000			01975 a2200565 4500
005			20250516030105.0
264		0	_c20110615
008			201106s 0 0 eng d
022			_a1474-4465
024	7		_a10.1016/S1474-4422(11)70020-5 _2doi
040			_aNLM _beng _cNLM
100	1		_aColes, Alasdair J
245	0	0	_aAlemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. _h[electronic resource]
260			_bThe Lancet. Neurology _cApr 2011
300			_a338-48 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdjuvants, Immunologic _xtherapeutic use
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAlemtuzumab
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal, Humanized
650	0	4	_aAntibodies, Neoplasm _xtherapeutic use
650	0	4	_aDisease-Free Survival
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aInterferon beta-1a
650	0	4	_aInterferon-beta _xtherapeutic use
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultiple Sclerosis, Relapsing-Remitting _xtherapy
650	0	4	_aSingle-Blind Method
650	0	4	_aTreatment Outcome
700	1		_aFox, Edward
700	1		_aVladic, Anton
700	1		_aGazda, Suzanne K
700	1		_aBrinar, Vesna
700	1		_aSelmaj, Krzysztof W
700	1		_aBass, Ann Doan-Do
700	1		_aWynn, Daniel R
700	1		_aMargolin, David H
700	1		_aLake, Stephen L
700	1		_aMoran, Susan
700	1		_aPalmer, Jeffrey
700	1		_aSmith, M Shelton
700	1		_aCompston, D Alastair S
773	0		_tThe Lancet. Neurology _gvol. 10 _gno. 4 _gp. 338-48
856	4	0	_uhttps://doi.org/10.1016/S1474-4422(11)70020-5 _zAvailable from publisher's website
999			_c20669571 _d20669571